Novartis Ag

Sandoz Gmbh

Lts Lohmann Therapie-systeme Gmbh + Co. Kg

Basf Se Corporation

Evonik Roehm Gmbh

Schwarz Pharma Ag

Lts Lohmann Therapie Systeme Gmbh & Co.

Perioc Ltd

Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh

Evonik Rohm Gmbh

Philipps-Universität Marburg

Transmit Gesellschaft Fur Technologietransfer Mbh

Justus-liebig-universität Gießen

Lab International Barbados, Srl

Thomas Kissel

David Bodmer

Hawkins V Maulding

Jones W Fong

Oskar Nagele

Jane E Pearson

Henriette Schrank

Hans-Rainer Hoffmann

Zdenek Brich

Andreas Greiner

Friedrich Richter

Frank Becher

Thomas Schmehl

Armin Breitenbach

Seema Agarwal

Liqun Ren

Tobias Jung

Xiaoying Wang

Youxin Li

Ching Pong Mak

Jurg Reinhardt

Harry Tiemessen

Walter Kamm

Michael Neu

Elke Kleemann

The present invention relates to novel treatments of periodontal disease by administering a suitable formulation of a cyclophilin inhibitor. The present invention further relates to novel pharmaceutical compositions containing said cyclophilin inhibitor compounds.

Pharmaceutical formulations and their use in the treatment of periodontal disease

The invention at hand provides hydrolytically degradable ionic copolymers. These ionic copolymerizates are composed of one cyclic ketene acetal A, one anionic or cationic methacrylic acid derivative B, selected from 2-methyl-methacrylate, [2-(2-methyl-1-methylene-allyloxy)]ethanesulfonate, [2-(2-methyl-1-methylene-allyloxy)ethyl]phosphonate or a quaternary amine of the N,N-dimethylaminoethylmethacrylic acid (DMAEMA) and, optionally, a neutral methacrylic acid derivative C. The hydrolytically degradable anionic copolymers according to the present invention are produced by polymerizing the components A, B and C in the presence of a radical initiator under inert gas atmosphere and subsequent purification. All copolymers according to the present invention are hydrolytically degradable. Copolymers comprising a maximum of 40 mol-% of ester groups in the backbone are additionally biodegradable, wherein in the case of cationic copolymers a maximum of 20 mol-% of quaternized DMAEMA is allowed to be available. Cationic copolymers comprising at least 50 mol-% of the component B are antimicrobial. Both anionic as well as cationic copolymers are suitable for producing nanoparticles. Cationic copolymers are suitable for being used as superhydrophobic materials as well as adhesives. Anionic copolymers are suitable for biodegradable thermoplastic elastomers and for biodegradable ionomers.

Hydrolytically decomposable ionic copolymers

The present invention relates to graft copolymers of polyvinyl sulfonic-co-vinyl alcohol)-g-poly(lactide-co-glycolide) (P(VS-VA)-g-PLGA) with negatively charged electrolyte properties, their method of preparation and their use. These negatively charged graft copolymers are suitable for effective loading and sustained-release of especially positively charged drugs, proteins and peptides, and drug-loaded particles from these grafted co-polymers are especially useful as parenteral or mucosal drug delivery systems for pharmaceutical applications.

Graft copolymers as drug delivery systems

Allylamine-containing liposomes

The invention is directed to self-assembling, polymer-based delivery systems for proteins. The delivery systems comprises an active agent and a polyol ester of the invention, having a linear polyol containing six or more hydroxyl groups as a central backbone and biodegradable hydroxy carboxylic ester groups attached to the central backbone.

Self-assembling colloidal carriers for protein delivery

The invention concerns a transdermal application system for antithrombotic therapy and for the prophylaxis against cancer, respectively, containing as active substance acetylsalicylic acid and/or pharmaceutically acceptable salts thereof.

Transdermal application system containing acetylsalicylic acid for antithrombotic therapy and cancer prophylaxis

Polyesters of a polyhydroxycarboxylic acid and a polyol having a

This invention provides a polyester of a polyol, said polyol containing at least 3 hydroxyl groups and having a molecular weight of up to 20,000 at least 1 hydroxyl group in said polyol being in the form of an ester, with a poly- or co-poly-lactic acid residue, each having a molecular weight of at least from 5,000. These are useful for parenteral depot formulations.

Polyol esters, their preparation and use in depot forms of

This invention provides a polyester of a polyol, said polyol containing at least 3 hydroxyl groups and having a molecular weight of up to 20,000 at least 1 hydroxyl group in said polyol being in the form of an ester, with a poly- or co-poly-lactic acid residue, each having a molecular weight of at least 5,000. These are useful for parenteral depot formulations.

The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide) glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.

Sustained release formulations of water soluble peptides

A transdermal therapeutic system for antithrombotic therapy is disclosed. The system comprises a hydrophobic polymer matrix, acetic anhydride, and acetylsalicylic acid as the only active ingredient.

Acetylsalicyclic acid-containing transdermal application system for

The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide)glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.

The present invention provides a pharmaceutical composition for the transdermal systemic administration of an active agent characterized in that the active agent is bopindolol or methysergide. Also the present invention provides a pharmaceutical composition for the transdermal systemic administration of a pharmacologically active agent characterized in that it contains bopindolol, tizanidine, clemastine, ketotifen or methysergide as active agent in a reservoir comprising a hydrophilic polymer. Furthermore a pharmaceutical composition for the transdermal systemic administration of pharmacologically active agents characterized in that the pharmacologically active agent is in a reservoir comprising a polyacrylate polymer containing cationic ester groups.

Pharmaceutical compositions

Growing community of inventors

Staufen, Germany

Thomas Kissel